Orexo’s annual report for 2012 released
Orexo’s annual report for the 2012 fiscal year has been published and can be downloaded from the investor section of the company’s homepage www.orexo.com.
For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46-18 780 88 50
Orexo AB is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue generating EU and US approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies. Orexo AB is headquartered in Sweden has 90 employees and is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap. For information about Orexo, please visit www.orexo.com.
Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 1:30pm CET on March 21, 2013.